Immunological effects of dimethyl fumarate treatment in blood and CSF of patients with primary progressive MS

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dimethyl fumarate is an efficient therapy used widely in patients with relapsing-remitting multiple sclerosis (RRMS). However, lacking effect of treatment has recently been reported in patients with primary progressive MS (PPMS) (Højsgaard Chow et al., 2021). In order to further analyze the immunological treatment response we investigated the systemic and intrathecal immunological effects of dimethyl fumarate (DMF) treatment in 50 patients with PPMS who participated in a 48-week randomized controlled trial with dimethyl fumarate vs placebo. We found substantial systemic immunomodulatory effects of DMF treatment comparable with those observed in patients with RRMS. However, intrathecal effects were limited and restricted to CD4+ T cells presumably resulting in higher concentrations of intrathecal IL-7.

TidsskriftJournal of Neuroimmunology
StatusUdgivet - 2021

Bibliografisk note

Funding Information:
We would like to thank our experienced laboratory technician, Lisbeth Egelykke Stolpe, for her invaluable assistance in analyzing blood and CSF samples. This study was funded by a grant from Biogen (Cambridge, MA, USA) , grants from the Danish Multiple Sclerosis Society ( A33491 , A35741 , and A38444 ) and a grant from His Royal Highness Christian X's Foundation . Biogen also supplied study drug and placebo free of charge.

Publisher Copyright:
© 2021 The Authors

Antal downloads er baseret på statistik fra Google Scholar og

Ingen data tilgængelig

ID: 284703184